FGFR2 and neoplasm: Of 30 patients tested, 29 had tumor-derived ctDNA detected but only 19 (63%) had confirmation of FGFR2/3 status as documented by local genotyping—12 had fusions and 7 had missense mutations (Supplementary Fig. S5).